IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
JP2000504336A
(en)
|
1996-02-02 |
2000-04-11 |
ゼネカ・リミテッド |
Heterocyclic compounds useful as pharmaceutical preparations
|
JP2001518067A
(en)
*
|
1996-04-03 |
2001-10-09 |
メルク エンド カンパニー インコーポレーテッド |
Inhibitors of farnesyl protein transferase
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2250143A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Jeffrey Bergman |
Inhibitors of farnesyl-protein transferase
|
CA2250192A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Chrisopher J. Dinsmore |
Inhibitors of farnesyl-protein transferase
|
EP0891335A4
(en)
*
|
1996-04-03 |
2001-08-16 |
Merck & Co Inc |
Inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2249601A1
(en)
*
|
1996-04-03 |
1997-10-23 |
Thorsten E. Fisher |
Inhibitors of farnesyl-protein transferase
|
JP2000504023A
(en)
*
|
1996-04-03 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
Cancer treatment methods
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2249559A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
IL128428A0
(en)
*
|
1996-08-14 |
2000-01-31 |
Zeneca Ltd |
Substituted pyrimidine derivatives and their pharmaceutical use
|
UA56197C2
(en)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Heterocyclic derivatives
|
AU6013998A
(en)
*
|
1996-12-30 |
1998-07-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1998035956A1
(en)
|
1997-02-13 |
1998-08-20 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
AU5999798A
(en)
|
1997-02-13 |
1998-09-08 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
WO1999010525A1
(en)
*
|
1997-08-27 |
1999-03-04 |
Merck & Co., Inc. |
A method of treating cancer
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
FR2774985A1
(en)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer
|
WO1999041242A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Rhone-Poulenc Rorer S.A. |
Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
|
AU5086499A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
AU3386600A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU3247700A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU3390000A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2362778A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819510B1
(en)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
|
FR2819512B1
(en)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
FR2819509B1
(en)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
BRPI0615934A2
(en)
|
2005-09-16 |
2011-05-31 |
Arrow Therapeutics Ltd |
compound or a pharmaceutically acceptable salt thereof, use of a biphenyl derivative, pharmaceutical composition, and, product
|
PL2474545T3
(en)
|
2005-12-13 |
2017-04-28 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US8436035B2
(en)
*
|
2006-12-18 |
2013-05-07 |
Novartis Ag |
Organic compounds
|
AU2008204380B2
(en)
|
2007-01-10 |
2013-08-15 |
Msd Italia S.R.L. |
Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
|
CN101679266B
(en)
|
2007-03-01 |
2015-05-06 |
诺华股份有限公司 |
PIM kinase inhibitors and methods of their use
|
BRPI0812159A2
(en)
|
2007-05-21 |
2017-05-02 |
Novartis Ag |
csf-1r inhibitors, compositions and methods of use
|
HUE043732T2
(en)
|
2007-06-13 |
2019-09-30 |
Incyte Holdings Corp |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
JP5913805B2
(en)
*
|
2007-10-05 |
2016-04-27 |
アキュセラ, インコーポレイテッド |
Alkoxy compounds for disease treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
WO2010105243A1
(en)
|
2009-03-13 |
2010-09-16 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
Inhibitors of akt activity
|
CA2758071C
(en)
|
2009-04-06 |
2018-01-09 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
|
AU2010249380B2
(en)
|
2009-05-22 |
2015-08-20 |
Incyte Holdings Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
|
CA2761954C
(en)
|
2009-05-22 |
2018-07-31 |
Incyte Corporation |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
JP6073677B2
(en)
|
2009-06-12 |
2017-02-01 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Fused heterocyclic compounds and their use
|
NZ597379A
(en)
|
2009-06-29 |
2014-04-30 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions
|
JP5860398B2
(en)
|
2009-07-02 |
2016-02-16 |
アキュセラ インコーポレイテッド |
Pharmacology of visual cycle modulators
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
BR112012008849A2
(en)
|
2009-10-14 |
2015-09-22 |
Schering Corp |
compound, pharmaceutical composition, and use of a compound
|
CA2793835C
(en)
|
2009-10-21 |
2021-07-20 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
CA2784807C
(en)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
AR081315A1
(en)
|
2010-03-10 |
2012-08-08 |
Incyte Corp |
HETEROCICLIC DERIVATIVES OF PIPERIDIN AND PIRIMIDIN -4-IL-AZETIDINA, A CRYSTALLINE FORM OF THE SALT OF ACETONITRILADIPICO ACID OF A PYRIMIDINIC DERIVATIVE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME THINGS WITH THE TREATMENT OF INJECTION , T
|
BR112012023021A2
(en)
|
2010-03-16 |
2016-05-31 |
Dana Farber Cancer Inst Inc |
indazole compounds and their uses
|
NZ603686A
(en)
|
2010-05-21 |
2014-11-28 |
Incyte Corp |
Topical formulation for a jak inhibitor
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
JP6043285B2
(en)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
RNA interference-mediated inhibition of catenin (cadherin-binding protein) β1 (CTNNB1) gene expression using small interfering nucleic acids (siNA)
|
HUE044815T2
(en)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
EA026201B1
(en)
|
2010-11-19 |
2017-03-31 |
Инсайт Холдингс Корпорейшн |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
JP5917544B2
(en)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
CA2821975A1
(en)
|
2010-12-17 |
2012-06-21 |
Shunqi Yan |
N-(4-(azetidine-1-carbonyl)phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase m2 pkm2 modulators
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
ES2569712T3
(en)
|
2010-12-21 |
2016-05-12 |
Agios Pharmaceuticals, Inc. |
PKM2 bicyclic activators
|
TWI549947B
(en)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
Therapeutic compounds and compositions
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
CN103608016A
(en)
|
2011-05-03 |
2014-02-26 |
安吉奥斯医药品有限公司 |
Pyruvate kinase activators for use in therapy
|
HUE039269T2
(en)
|
2011-05-03 |
2018-12-28 |
Agios Pharmaceuticals Inc |
Pyruvate kinase activators for use in therapy
|
CN102827073A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Therapeutically active compositions and application methods thereof
|
CN102827170A
(en)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
Active treatment compositions and use method thereof
|
AR086983A1
(en)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
DERIVATIVES OF AZETIDINIL FENIL, PIRIDIL OR PIRAZINIL CARBOXAMIDA AS JAK INHIBITORS
|
TW201313721A
(en)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
Cyclohexyl azetidine derivatives as JAK inhibitors
|
UA111854C2
(en)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
CN104379563B
(en)
*
|
2012-04-10 |
2018-12-21 |
加利福尼亚大学董事会 |
Composition and method for treating cancer
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
AR091079A1
(en)
|
2012-05-18 |
2014-12-30 |
Incyte Corp |
DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US10112927B2
(en)
|
2012-10-18 |
2018-10-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
PL2919766T3
(en)
|
2012-11-15 |
2021-10-04 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
BR112015012295A8
(en)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER
|
BR112015013611A2
(en)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
compound and pharmaceutical composition
|
EP2951180B1
(en)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
AU2014225938B2
(en)
|
2013-03-06 |
2018-07-19 |
Incyte Holdings Corporation |
Processes and intermediates for making a JAK inhibitor
|
CA2905751A1
(en)
|
2013-03-13 |
2014-10-09 |
Forma Therapeutics, Inc. |
Novel compounds and compositions for inhibition of fasn
|
US10376510B2
(en)
|
2013-07-11 |
2019-08-13 |
Agios Pharmaceuticals, Inc. |
2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
MX2016001639A
(en)
|
2013-08-07 |
2016-10-07 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor.
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
JP6491202B2
(en)
|
2013-10-18 |
2019-03-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7)
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
KR20220070066A
(en)
|
2014-03-14 |
2022-05-27 |
아지오스 파마슈티컬스 아이엔씨. |
Pharmaceutical compositions of therapeutically active compounds
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
JO3589B1
(en)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
Protein kinase c inhibitors and methods of their use
|
BR112017008416B1
(en)
|
2014-10-24 |
2023-05-09 |
Landos Biopharma, Inc |
THERAPEUTIC PRODUCTS BASED ON LANTHIONINE SYNTETASE C-LIKE 2
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
WO2016160617A2
(en)
|
2015-03-27 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
SI3307271T1
(en)
|
2015-06-11 |
2023-11-30 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP3347018B1
(en)
|
2015-09-09 |
2021-09-01 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
UA123401C2
(en)
|
2015-10-15 |
2021-03-31 |
Аджиос Фармасьютікалз, Інк. |
Combination therapy for treating malignancies
|
BR122024000250A2
(en)
|
2015-10-15 |
2024-02-27 |
Les Laboratoires Servier |
USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT
|
JOP20190055A1
(en)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
Anti-cd27 antibodies
|
JP7160833B2
(en)
|
2017-04-13 |
2022-10-25 |
サイロパ ビー.ブイ. |
anti-SIRP alpha antibody
|
WO2018236745A1
(en)
|
2017-06-20 |
2018-12-27 |
Carnot, Llc |
Compositions and methods for increasing efficiency of cardiac metabolism
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
DK3746429T3
(en)
|
2018-01-30 |
2022-05-02 |
Incyte Corp |
PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON)
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(en)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
Preparation method of imidazole methylamine derivative
|
UA127925C2
(en)
|
2018-03-30 |
2024-02-14 |
Інсайт Корпорейшн |
Treatment of hidradenitis suppurativa using jak inhibitors
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
TWI767148B
(en)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
Inhibiting fatty acid synthase (fasn)
|
EP3873214A4
(en)
|
2018-10-29 |
2022-07-13 |
Forma Therapeutics, Inc. |
Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
MX2022001915A
(en)
|
2019-12-20 |
2022-03-17 |
Landos Biopharma Inc |
Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same.
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|